Altimmune(US:ALT) Globenewswire·2025-09-24 21:14Core Viewpoint - Rosen Law Firm is reminding investors who purchased Altimmune, Inc. securities between August 10, 2023, and June 25, 2025, about the lead plaintiff deadline of October 6, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - A class action lawsuit has been filed against Altimmune, and investors can join the action without any out-of-pocket fees through a contingency fee arrangement [1][2]. - Investors wishing to serve as lead plaintiff must file with the Court by October 6, 2025, to represent other class members in the litigation [2]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has been consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. Group 3: Case Background - The lawsuit alleges that Altimmune misrepresented the results of its IMPACT Phase 2b MASH trial, claiming they had reliable information while failing to meet a key statistical significance marker for fibrosis reduction [4]. - The company is accused of inflating expectations for positive results while concealing adverse data from the placebo group, which negatively impacted the trial's topline results [4].